Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors

Background: The standard treatment in postmenopausal women with estrogen- and progesterone-positive localized breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen frailty syndrome over time and the relationship with changes in gonadal hormones concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Sánchez, Javier, Mafla-España, Mayra Alejandra, Torregrosa, María Dolores, Cauli, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312841/
https://www.ncbi.nlm.nih.gov/pubmed/35884939
http://dx.doi.org/10.3390/biomedicines10071634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312841/
https://www.ncbi.nlm.nih.gov/pubmed/35884939
http://dx.doi.org/10.3390/biomedicines10071634

Ejemplares similares